blood test intended News
-
FDA grants Breakthrough Device Designation for Seravue® to support earlier diagnosis of Liver Cancer using a simple blood test
Pennsylvania June 8th, 2020: The FDA has granted Breakthrough Device Designation for Seravue® to support earlier diagnosis of Liver Cancer using a simple blood test. Seravue® is intended for use as an aid in the diagnosis of Hepatocellular Carcinoma (HCC), including early stage HCC, in patients with an elevated risk of developing HCC, in conjunction with ultrasound imaging or alone in ...
-
FDA grants Breakthrough Device Designation for Seravue® to support earlier diagnosis of Liver Cancer using a simple blood test
Pennsylvania June 8th, 2020: The FDA has granted Breakthrough Device Designation for Seravue® to support earlier diagnosis of Liver Cancer using a simple blood test. Seravue® is intended for use as an aid in the diagnosis of Hepatocellular Carcinoma (HCC), including early stage HCC, in patients with an elevated risk of developing HCC, in conjunction with ultrasound imaging or alone in ...
-
C2N Opens State-of-the-Art CLIA Lab in St. Louis as Alzheimer’s Disease Blood Diagnostic Test Bests Others in Independent Comparison Studies Published in JAMA Neurology
On World Alzheimer’s Day, Missouri leaders and economic development officials praise C2N Diagnostics for deciding to continue to grow its St. Louis-based company which is receiving international recognition for developing and accelerating novel diagnostics and therapies for Alzheimer’s disease. C2N Diagnostics has expanded its lab facilities to 13,320 square feet in the Cortex ...
-
Major Research Findings Highlight Effectiveness of the PrecivityAD™ Blood Test That Clinicians Use to Aid in Alzheimer’s Disease Diagnosis
Four separate research reports presented at premier Alzheimer’s disease and aging conferences add to the increasing set of details about the accuracy and clinical usefulness of the PrecivityAD™ blood test from C2N Diagnostics. The PrecivityAD™ test is a breakthrough blood test intended for use in patients with cognitive impairment. The test helps physicians determine the ...
-
Peer-Reviewed Journal Publishes Analytical Validation Results for the PrecivityAD Blood Test, Which Can Help Clinicians Detect Alzheimer’s Disease
C2N Diagnostics, which offers the PrecivityAD™ blood test that can help detect if certain markers for Alzheimer’s disease are in the brain, now has its analytical validation results available for review. The study appears in Clinica Chimica Acta, the official peer-reviewed journal of the International Federation of Clinical Chemistry and Laboratory Medicine. The article is titled ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you